

Accompanying Documents

1. Marked-up copies of the originally presented claims incorporating the amendments made herein (Appendix A).
2. Clean copies of the pending claims after incorporation of the amendments made herein (Appendix B).

AMENDMENT

In the Claims:

Please amend claims 1, 13, 16, 34, 38, 40, 42, and 43, without prejudice or disclaimer, as follows:

B1
Amended
1. A low salt-containing aqueous composition comprising biologically active human IGF-I or biologically active variant thereof in a concentration of at least about 250 mg/ml and a pH greater than about pH 5.0, wherein said variant is a polypeptide that has at least 80% amino acid sequence identity to amino acid sequence of the human IGF-I.

B2 43. A kit for reconstituting a pharmaceutical composition comprising biologically active human IGF-I or biologically active variant thereof, said kit comprising the composition of claim 1 and separately a pharmaceutically acceptable buffered solution having a pH less than or equal to pH 5.0.

q/c B 35 16. A pharmaceutical composition comprising the composition of claim 1, and a pharmaceutically acceptable carrier and/or excipient.

B4 34 34. A low salt-containing aqueous composition comprising biologically active human IGF-I in a concentration of at least about 250 mg/ml and a pH greater than about pH 5.0.

20 38. A pharmaceutical composition comprising the composition of claim 16, and a pharmaceutically acceptable carrier and/or excipient.

22 40. A pharmaceutical composition comprising the composition of claim 34, and a pharmaceutically acceptable carrier and/or excipient.

32²

B